Mater Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cancer, Neurology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers’ and Babies Health. Clinical trials are an essential component of healthcare. They provide the evidence to evaluate the safety and efficacy of new treatments and diagnostics, and provide alternative treatment options for patients with unmet needs.
Mater currently has over 200 active clinical trials. These trials include commercial pharmaceutical and medical device studies, as well as collaborative group studies and investigator-initiated studies, led by Mater’s researchers and collaborators at The University of Queensland and other leading Australian and international medical research institutions.
Without volunteers, clinical trials are not possible. If you are interested in being involved – you may be a patient with a new diagnosis, a patient with a long term diagnosis or a healthy volunteer – view available trials below or contact the Mater Clinical Trials team.
Clinical Trials are divided into the following categories:
Enhancing treatment outcomes after after gynaecological cancer through exercise
Trial Status:
Not yet recruiting
|
The purpose of the study is to test whether the addition of an immunotherapy drug, called tislelizumab, to the standard of care treatment of high-risk endometrial cancer reduces the risk of the disease coming back, and to determine if the new course of therapy is well-tolerated by participants.
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study Evaluating Efficacy, Safety and Tolerability of BI 1291583 qd Over at Least 24 Weeks in Patients with Bronchiectasis (Airleaf™)
This study will investigate the use of a new medicine called AMT-151 which may be used in the future as a possible treatment for advanced solid tumours.
The research study is testing a new way of taking hormone tablets for prostate cancer. The new method is called ‘adaptive therapy,’ also known as a pause/restart strategy.
This study will investigate the use of a new medicine called sacituzumab govitecan (Trodelvy®) when compared to standard of care chemotherapy.
This study will investigate the use of a new medicine called sacituzumab govitecan (Trodelvy®) combined with pembrolizumab when compared to standard of care chemotherapy.
A trial studying the safety & effectiveness of a new injection therapy for the treatment of ulcerative colitis.
The study is testing a new treatment for triple negative breast cancer. The new treatment includes four drugs called atezolizumab, bevacizumab, gemcitabine, and carboplatin.
The purpose of this study is to compare the effects, good or bad of an investigational product, capivasertib added to standard treatments in patients who are newly diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) and your cancer has low levels of a protein called PTEN (or “PTEN deficiency”).
Trial Status:
Active, not recruiting
|